Abstract
Inducing degradation of undruggable target proteins by the use of chimeric small molecules, represented by proteolysis-targeting chimeras, is a promising strategy for drug development. We developed a series of chimeric molecules, termed “specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers” (SNIPERs) that recruit IAP ubiquitin ligases to induce degradation of target proteins. SNIPERs also induce degradation of some IAPs, including cIAP1 and XIAP, which are antiapoptotic proteins that are overexpressed in many cancers. Such protein degraders have unique properties that could be especially useful in cancer therapy. This chapter describes (1) the design and synthesis of SNIPER compounds, (2) the methods used for the detection of target protein degradation and ubiquitylation, and (3) the protocol to evaluate the antitumor activity of SNIPER.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Okuhira K, Ohoka N, Sai K et al (2011) Specific degradation of CRABP-II via cIAP1- mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett 585:1147–1152
Itoh Y, Ishikawa M, Naito M et al (2010) Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J Am Chem Soc 132:5820–5826
Itoh Y, Ishikawa M, Kitaguchi R et al (2011) Development of target protein-selective degradation inducer for protein knockdown. Bioorg Med Chem 19:3229–3241
Itoh Y, Kitaguchi R, Ishikawa M et al (2011) Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg Med Chem 19:6768–6778
Itoh Y, Ishikawa M, Kitaguchi R et al (2012) Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorg Med Chem Lett 22:4453–4457
Ohoka N, Nagai K, Hattori T et al (2014) Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis 5:e1513
Okuhira K, Demizu Y, Hattori T et al (2013) Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci 11:1492–1498
Ohoka N, Okuhira K, Ito M et al (2017) In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). J Biol Chem 11:4556–4570
Ohoka N, Morita Y, Nagai K et al (2018) Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation. J Biol Chem 18:6776–6790
Okuhira K, Demizu Y, Hattori T et al (2016) Molecular design, synthesis, and evaluation of SNIPER(ER) that induces proteasomal degradation of ERα. Methods Mol Biol 1366:549–560
Saito M, Aoyagi T, Umezawa H et al (1976) Bestatin, a new specific inhibitor of aminopeptidases, enhances activation of small lymphocytes by concanavalin A. Biochem Biophys Res Commun 76:526–533
Umezawa H, Aoyagi T, Suda H et al (1976) Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot 29:97–99
Sekine K, Takubo K, Kikuchi R et al (2008) Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J Biol Chem 283:8961–8968
Shibata N, Miyamoto N, Nagai K et al (2017) Development of protein degradation inducers of oncogenic BCR- ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci 108:1657–1666
Veach DR, Namavari M, Pillarsetty N et al (2007) Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 50:5853–5857
Winter GE, Buckley DL, Paulk J et al (2015) Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348:1376–1381
Govek SP, Oshiro G, Anzola JV et al (2010) Water-soluble PDE4 inhibitors for the treatment of dry eye. Bioorg Med Chem Lett 20:2928–2932
Acknowledgments
This study was supported by MEXT/JSPS KAKENHI (grants JP19K07724 and JP16K18444 to Y.T., JP19K16333 to G.T., JP18K07311 to N.S., JP18K06567 to N.O., JP17K08385 to Y.D., JP16H05090, and JP18H05502 to M.N.) and by AMED (grants JP17cm0106522j0002 to N.S., JP19cm0106136, JP19ak0101073 to N.O., JP19ak0101073j0603, and JP19im0210616j0002 to M.N.). We are grateful to Journal of Biological Chemistry and the American Society for Biochemistry and Molecular Biology (ASBMB) for allowing the reproduction of Figs. 5, 6, and 7, which were originally published in the Journal of Biological Chemistry [8] (Ohoka N, Okuhira K, Ito M et al. In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). J Biol Chem. 2017; 11:4556–4570. © the American Society for Biochemistry and Molecular Biology.) We also thank Marla Brunker, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Tsukumo, Y. et al. (2021). Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects. In: Cacace, A.M., Hickey, C.M., Békés, M. (eds) Targeted Protein Degradation. Methods in Molecular Biology, vol 2365. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1665-9_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1665-9_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1664-2
Online ISBN: 978-1-0716-1665-9
eBook Packages: Springer Protocols